Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 853086, 13 pages
http://dx.doi.org/10.1155/2014/853086
Research Article

A RXR Ligand 6-OH-11-O-Hydroxyphenanthrene with Antitumour Properties Enhances (−)-Epigallocatechin-3-gallate Activity in Three Human Breast Carcinoma Cell Lines

1Department of Pharmacology and Biotechnology (FaBiT), University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy
2Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy
3Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
4Department of Biological, Geological, and Environmental Sciences, (BiGea), University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy

Received 10 February 2014; Accepted 5 May 2014; Published 11 June 2014

Academic Editor: Beatrice Charreau

Copyright © 2014 Fulvia Farabegoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Wolfram, “Effects of green tea and EGCG on cardiovascular and metabolic health,” Journal of the American College of Nutrition, vol. 26, no. 4, pp. S73–S388, 2007. View at Google Scholar · View at Scopus
  2. Y. Clement, “Can green tea do that? A literature review of the clinical evidence,” Preventive Medicine, vol. 49, no. 2-3, pp. 83–87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Yuan, C. Sun, and L. M. Butler, “Tea and cancer prevention: epidemiological studies,” Pharmacological Research, vol. 64, no. 2, pp. 123–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Kanwar, M. Taskeen, I. Mohammad, C. Huo, T. H. Chan, and Q. P. Dou, “Recent advances on tea polyphenols,” Frontiers in Bioscience, vol. 4, pp. 111–131, 2012. View at Google Scholar · View at Scopus
  5. B. N. Singh, S. Shankar, and R. K. Srivastava, “Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications,” Biochemical Pharmacology, vol. 82, no. 12, pp. 1807–1821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. S. Yang, H. Wang, G. X. Li, Z. Yang, F. Guan, and H. Jin, “Cancer prevention by tea: evidence from laboratory studies,” Pharmacological Research, vol. 64, no. 2, pp. 113–122, 2011. View at Google Scholar
  7. C. S. Yang and H. Wang, “Mechanistic issues concerning cancer prevention by tea catechins,” Molecular Nutrition and Food Research, vol. 55, no. 6, pp. 819–831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Henning, Y. Niu, Y. Liu et al., “Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals,” Journal of Nutritional Biochemistry, vol. 16, no. 10, pp. 610–616, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Lee, M. Kishikawa, M. Kumazoe, K. Yamada, and H. Tachibana, “Vitamin A enhances antitumor effect of a green tea polyphenol on melanoma by upregulating the polyphenol sensing molecule 67-kDa laminin receptor,” PLoS ONE, vol. 5, no. 6, Article ID e11051, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Mi, “Current treatment strategy of acute promyelocytic leukemia,” Frontiers of Medicine in China, vol. 5, no. 4, pp. 341–347, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Nelson, N. V. Mcferran, G. Pivato et al., “The 67 kDa laminin receptor: structure, function and role in disease,” Bioscience Reports, vol. 28, no. 1, pp. 33–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Tachibana, K. Koga, Y. Fujimura, and K. Yamada, “A receptor for green tea polyphenol EGCG,” Nature Structural and Molecular Biology, vol. 11, no. 4, pp. 380–381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Umeda, S. Yano, K. Yamada, and H. Tachibana, “Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor,” Journal of Biological Chemistry, vol. 283, no. 6, pp. 3050–3058, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Umeda, S. Yano, K. Yamada, and H. Tachibana, “Involvement of 67-kDa laminin receptor-mediated myosin phosphatase activation in antiproliferative effect of epigallocatechin-3-O-gallate at a physiological concentration on Caco-2 colon cancer cells,” Biochemical and Biophysical Research Communications, vol. 371, no. 1, pp. 172–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. Anzano, S. W. Byers, J. M. Smith et al., “Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen,” Cancer Research, vol. 54, no. 17, pp. 4614–4617, 1994. View at Google Scholar · View at Scopus
  16. M. A. Anzano, C. W. Peer, J. M. Smith et al., “Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid,” Journal of the National Cancer Institute, vol. 88, no. 2, pp. 123–125, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bryan, E. D. Pulte, K. C. Toomey et al., “A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer,” Investigational New Drugs, vol. 29, no. 6, pp. 1482–1487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. G. T. Budd, P. C. Adamson, M. Gupta et al., “Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer,” Clinical Cancer Research, vol. 4, no. 3, pp. 635–642, 1998. View at Google Scholar · View at Scopus
  19. M. Cazzaniga, C. Varricchio, C. Montefrancesco, I. Feroce, and A. Guerrieri-Gonzaga, “Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 172897, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Wu, Y. Zhang, X.-C. Xu et al., “The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice,” Cancer Research, vol. 62, no. 22, pp. 6376–6380, 2002. View at Google Scholar · View at Scopus
  21. I. P. Uray and P. H. Brown, “Chemoprevention of hormone receptor-negative breast cancer: new approaches needed,” Recent Results in Cancer Research, vol. 188, pp. 147–162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Bartolini, M. Orlandi, A. Papi et al., “A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells,” In Vivo A, vol. 20, no. 6, pp. 729–734, 2006. View at Google Scholar · View at Scopus
  23. A. Papi, P. Rocchi, A. M. Ferreri, and M. Orlandi, “RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells,” Cancer Letters, vol. 297, no. 1, pp. 65–74, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Papi, T. Guarnieri, G. Storci et al., “Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells,” Cell Death and Differentiation, vol. 19, no. 7, pp. 1208–1219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Montesinos and M. A. Sanz, “The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 3, Article ID e2011059, 2011. View at Google Scholar
  26. F. Farabegoli, C. Barbi, E. Lambertini, and R. Piva, “(−)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells,” Cancer Detection and Prevention, vol. 31, no. 6, pp. 499–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Romanelli, P. Perego, G. Pratesi, N. Carenini, M. Tortoreto, and F. Zunino, “In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems,” Cancer Chemotherapy and Pharmacology, vol. 41, no. 5, pp. 385–390, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Chomczynski and N. Sacchi, “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,” Analytical Biochemistry, vol. 162, no. 1, pp. 156–159, 1987. View at Google Scholar · View at Scopus
  29. C. C. Kuo and S. C. Lin, “Altered FOXO1 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients,” Molecular Medicine, vol. 13, no. 11-12, pp. 561–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Liu, L. Sun, P. Zhao et al., “Hypoxia promotes metastasis in human gastric cancer by up-regulating the 67-kDa laminin receptor,” Cancer Science, vol. 101, no. 7, pp. 1653–1660, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. M. J. Scandlyn, E. C. Stuart, T. J. Somers-Edgar, A. R. Menzies, and R. J. Rosengren, “A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate,” British Journal of Cancer, vol. 99, no. 7, pp. 1056–1063, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. C. M. Chang, P. Y. Chang, M. G. Tu et al., “Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2,” Oncology Reports, vol. 28, no. 5, pp. 1799–1807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. N. Tang, J. Fu, S. Shankar, and R. K. Srivastava, “EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer,” PLoS ONE, vol. 7, no. 2, Article ID e31067, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Suganuma, A. Saha, and H. Fujiki, “New cancer treatment strategy using combination of green tea catechins and anticancer drugs,” Cancer Science, vol. 102, no. 2, pp. 317–323, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Singh, K. Bhui, R. Singh, and Y. Shukla, “Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis,” Life Sciences, vol. 93, no. 1, pp. 7–16, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Farabegoli, A. Papi, and M. Orlandi, “(−)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells,” Bioscience Reports, vol. 31, no. 2, pp. 99–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Lefebvre, Y. Benomar, and B. Staels, “Retinoid X receptors: common heterodimerization partners with distinct functions,” Trends in Endocrinology and Metabolism, vol. 21, no. 11, pp. 676–683, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. A. Lawrence, M. J. Merino, J. F. Simpson, R. E. Manrow, D. L. Page, and P. S. Steeg, “A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor,” Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 1, pp. 29–35, 1998. View at Google Scholar · View at Scopus
  40. M. Friedrich, R. Axt-Fliedner, C. Villena-Heinsen, W. Tilgen, W. Schmidt, and J. Reichrath, “Analysis of vitamin D-receptor (VDR) and retinoid X-receptor α in breast cancer,” Histochemical Journal, vol. 34, no. 1-2, pp. 35–40, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Z. Fang, Y. Wang, N. Ai et al., “Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines,” Cancer Research, vol. 63, no. 22, pp. 7563–7570, 2003. View at Google Scholar · View at Scopus
  42. F. Ye, G.-H. Zhang, B.-X. Guan, and X.-C. Xu, “Suppression of esophageal cancer cell growth using curcumin, (−)-epigallocatechin-3-gallate and lovastatin,” World Journal of Gastroenterology, vol. 18, no. 2, pp. 126–135, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. L. J. Gudas and J. A. Wagner, “Retinoids regulate stem cell differentiation,” Journal of Cellular Physiology, vol. 226, no. 2, pp. 322–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Bianco, N. P. Castro, C. Baraty et al., “Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells,” Journal of Cellular Physiology, vol. 228, no. 6, pp. 1174–1188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. N. C. Turner and J. S. Reis-Filho, “Tackling the diversity of triple-negative breast cancer,” Clinical Cancer Research, vol. 19, pp. 6380–6388, 2013. View at Google Scholar
  46. J. Y. Yang and M. C. Hung, “A new fork for clinical application: targeting forkhead transcription factors in cancer,” Clinical Cancer Research, vol. 15, no. 3, pp. 752–757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Huang and D. J. Tindall, “FOXO transcription factors in cell-cycle regulation and the response to oxidative stress,” Future Oncology, vol. 2, pp. 83–89, 2006. View at Google Scholar
  48. R. B. Riggins, R. S. Schrecengost, M. S. Guerrero, and A. H. Bouton, “Pathways to tamoxifen resistance,” Cancer Letters, vol. 256, no. 1, pp. 1–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. F. Eddy, S. E. Kane, and G. E. Sonenshein, “Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate,” Cancer Research, vol. 67, no. 19, pp. 9018–9023, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Belguise, S. Guo, and G. E. Sonenshein, “Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor α expression reversing invasive phenotype of breast cancer cells,” Cancer Research, vol. 67, no. 12, pp. 5763–5770, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Sakoe, K. Sakoe, K. Kirito, K. Ozawa, and N. Komatsu, “FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia,” Blood, vol. 115, no. 18, pp. 3787–3795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. J. D. Col, K. Mastorci, D. A. Fae et al., “Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets,” Cancer Research, vol. 72, no. 7, pp. 1825–1835, 2012. View at Publisher · View at Google Scholar · View at Scopus